Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Fighting Omicron: This Covid Vaccine Candidate Is Going After The Dangerous Mutation

CureVac N.V.  (NASDAQ:CVAC) and GSK plc (NYSE:GSK) have started a Phase 1 trial of the modified COVID-19 mRNA vaccine candidate, administered as a…
byVandana Singh
August 18, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0
  • CureVac N.V.  (NASDAQ:CVAC) and GSK plc (NYSE:GSK) have started a Phase 1 trial of the modified COVID-19 mRNA vaccine candidate, administered as a booster dose to previous COVID-19 vaccination.
  • The candidate, CV0501, is meant to be administered as a booster dose following the previous COVID-19 vaccination. GSK used CureVac’s “second-generation mRNA backbone” to develop the vaccine.
  • CureVac will test CV0501 in up to 180 healthy, COVID-19 vaccinated adults. The participants will receive a single booster dose in the dose range of 12µg to 50µg at first.
  • Related: BioNTech, Pfizer File For Clearance Over COVID-19 Vaccine Patent Dispute With CureVac.
  • Additional dose levels below 12µg and above 50µg may be evaluated if supported by safety and immunogenicity data at these dose levels.
  • In March, the company also kicked off a phase 1 test for a “second-generation” COVID-19 shot called CV2CoV.
  • The company said this double-pronged approach would help identify the best-performing candidate for later-stage clinical development.
  • Data from the two studies will be reported together, although CureVac did not say when. 
  • Price Action: CVAC shares are down 0.08% at $13.17, and GSK stock is down 1.92% at $34.04 on the last check Thursday.
  • Photo by Gerd Altmann from Pixabay
 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts
Read More

5 Value Stocks To Watch In The Real Estate Sector

By Benzinga Insights
July 25, 10:56 AM
Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most likely be labelled as a value stock.

AJX